Insight

Hidehito Horinouchi: Impact of Durvalumab on corticosteroid therapy for pneumonitis after chemoradiotherapy

Photo taken from Hidehito Horinouchi/X

Aug 13, 2024, 20:25

Hidehito Horinouchi: Impact of Durvalumab on corticosteroid therapy for pneumonitis after chemoradiotherapy

Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, shared on X:

“Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.

Saori Murata, Hidehito Horinouchi, Clinical Lung Cancer.

Representation of duration and complexity of tapering patterns.”

Hidehito Horinouchi

Source: Hidehito Horinouchi/X

Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.

Authors: Saori Murata, Hidehito Horinouchi, Momoko Morishita, Sawako Kaku, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Tairo Kashihara, Kae Okuma, Masahiko Kusumoto, and Yuichiro Ohe.

Hidehito Horinouchi

cancer Clinical Lung Cancer Corticosteroid Therapy Durvalumab Hidehito Horinouchi Kae Okuma Masahiko Kusumoto Momoko Morishita Noboru Yamamoto OncoDaily Oncology pneumonitis Saori Murata Sawako Kaku Tairo Kashihara Tatsuya Yoshida Yasushi Goto Yuichiro Ohe Yuki Shinno Yusuke Okuma

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage